COLON CANCER NEWS TIPS & FEATURES


OMNI Health Media is a leading online provider of Daily Health News. OMNI’s Erbitux News provides summaries of developments in the prevention, screening, and management of Gastrointestinal Health Conditions as they are discovered and reported by physicians and scientists around the world. Our mission is to provide this news, including results of recent clinical trials evaluating new therapies and supportive care strategies in order to better educate patients and their caregivers, ensuring timely access to the best care available.
Managing Side Effects From EGFR Inhibitors

April 10, 2018

Managing Side Effects From EGFR Inhibitors

By Anonymous User anonymous_user_10987

CancerConnect News: Epidermal Growth Factor Receptor (EGFR) inhibitor drugs are a type of precision cancer medicine commonly used to treat lung, colon, head and neck and other cancers that over express the EGFR.  There are several EGFR inhibitor drugs and these cause similar side effects. The EGFR pathway is a normal biologic pathway found in […]

View full entry

Tags: cetuximab, Colon Cancer, diarrhea, EGFR inhibitors, erbitux, Erlotinib, Gefitinib, Head and Neck Cancer, iressa, Lung Cancer, News Tips and Features, News Tips and Features Other


Targeting both BRAF and EGFR doubles progression-free survival in metastatic colorectal cancer

October 16, 2017

Targeting both BRAF and EGFR doubles progression-free survival in metastatic colorectal cancer

By Anonymous User anonymous_user_10987

Recent successes in genetically targeted precision cancer medicines are improving outcomes in a number of cancers.  Ensuring patients undergo genomic sequencing to determine if they have treatable targets is increasingly important to ensure patients receive the most appropriate personalized care. Precision cancer medicine utilizes molecular diagnostic testing, including DNA sequencing, to identify cancer-driving abnormalities in […]

View full entry

Tags: BRAF, Colon Cancer, erbitux, News Tips and Features, News Tips and Features Other, Precision Cancer Medicine, Rectal Cancer, V600E, vemurafenib, Zelboraf


Erbitux Appears Superior to Avastin for Initial Colorectal Cancer Therapy

January 13, 2015

Erbitux Appears Superior to Avastin for Initial Colorectal Cancer Therapy

By Anonymous User anonymous_user_10987

Results of the phase III “Fire” trials were recently published in the medical journal The Lancet Oncology. The results of the study suggest that patients with metastatic colorectal cancer treated with Erbitux (cetuximab) combined with standard first-line FOLFIRI chemotherapy survive longer compared with FOLFIRI plus Avastin (bevacizumab). The study analyzed data from 592 patients with […]

View full entry

Tags: avastin, Colon Cancer, colorectal cancer, erbitux, News Tips and Features, News Tips and Features Other, Stage IV (D)/Relapsed Colon Cancer


Chemotherapy Regimens paired with Avastin or Erbitux Extended Survival for Patients with Metastatic Colorectal Cancer

June 20, 2014

Chemotherapy Regimens paired with Avastin or Erbitux Extended Survival for Patients with Metastatic Colorectal Cancer

By Anonymous User anonymous_user_10987

In a plenary session of the American Society of Clinical Oncology (ASCO) meeting in Chicago, researchers reported that treatment of metastatic colorectal cancer with Avastin® (bevacizumab) or Erbitux® (cetuximab) and standard chemotherapy (FOLFOX or FOLFIRI) regimens led to a new benchmark median survival time of 29 months. The results presented as ASCO were from the […]

View full entry

Tags: asco, avastin, Colon Cancer, colorectal cancer, erbitux, News Tips and Features, News Tips and Features Other, Rectal Cancer, Recurrent/Relapsed Rectal Cancer, Stage IV (D)/Relapsed Colon Cancer, Stage IV Rectal Cancer


View more articles like this
More news and in-depth Colon Cancer information

CONDITIONS OF THE GI TRACT